Cozaar XQ Re-examination Study (MK-0954-349)

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Amlodipine; Losartan

Criteria

Inclusion criteria:

• Participant with essential hypertension

• Participant who is treated with COZAAR XQ within local label for the first time

Exclusion criteria:

• Participant who is treated with COZAAR XQ before contract and out of enrollment period

• Participant who has a contraindication to COZAAR XQ according to the local label